Torren Management’s Travere Therapeutics TVTX Stock Holding History

Torren Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-998	Closed	-$38.1K	–	1429
2025 Q4	$38.1K	Buy	+998	New	+$32.5K	0.02%	399

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Torren Management's TVTX Position: Q1 2026 in Review

Torren Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 998 shares — an estimated $38.1K sold.

Torren Management first reported a position in TVTX in Q4 2025 and held it in 1 quarter. The position peaked at $38.1K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Torren Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
Torren Management sold 998 Travere Therapeutics shares in Q1 2026, an estimated $38.1K.
Torren Management first reported a position in Travere Therapeutics in Q4 2025 and held it in 1 quarter.
Torren Management's Travere Therapeutics position peaked at $38.1K in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.